In a report released yesterday, Biren Amin from Jefferies reiterated a Buy rating on Lion Biotechnologies Inc (NASDAQ: LBIO), with a price target of $11. The company’s shares closed yesterday at $6.

According to TipRanks.com, Amin is a 3-star analyst with an average return of 2.4% and a 49.1% success rate. Amin covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Bellicum Pharmaceuticals, and Anthera Pharmaceuticals.

Currently, the analyst consensus on Lion Biotechnologies Inc is Strong Buy and the average price target is $14, representing a 133.3% upside.

In a report issued on May 2, Roth Capital also reiterated a Buy rating on the stock with a $14 price target.

The company has a one year high of $9.58 and a one year low of $4.94. Currently, Lion Biotechnologies Inc has an average volume of 257.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lion Biotechnologies, Inc. operates as a biotechnology company which focuses on the development and commercialization of novel cancer immunotherapy. It products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The company services include adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma. Lion Biotechnologies was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.